Change in cognitive function has been adopted by a recent Phase II clinical trial15, but if different trajectories in cognitive decline are primarily driven by GBA1 status, the effect of disease-modifying therapies on cognition might be confounded. Here, GBA1 is linked to Mental deterioration.